tert-butyl 4-(4-chloro-3-methylphenyl)piperazine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl 4-(4-chloro-3-methylphenyl)piperazine-1-carboxylate
• 化学式: C₁₆H₂₃ClN₂O₂
• 分子量: 310.824
• InChiKey: UQOQXRAVMRITLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(4-chloro-3-methylphenyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以76%的产率得到1-(4-chloro-3-methylphenyl)piperazine
  参考文献：
  名称：

  Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

  摘要：

  A persistent latent reservoir of virus in CD4(+) T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC(50)s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112254
• 作为产物：
  描述：

  5-溴-2-氯甲苯 、 N-Boc-哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 以84%的产率得到tert-butyl 4-(4-chloro-3-methylphenyl)piperazine-1-carboxylate
  参考文献：
  名称：

  [EN] ARYL- AND HETEROARYL-RESORUFIN DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS AND LIVER AND KIDNEY DISORDERS
  [FR] DÉRIVÉS D'ARYLE ET D'HÉTÉROARYLE-RÉSORUFINE POUR LE TRAITEMENT DE TROUBLES DE STRESS OXYDATIF ET DE TROUBLES HÉPATIQUES ET RÉNAUX

  摘要：

  本文披露了一种化合物及使用这种化合物治疗或抑制氧化应激性疾病的方法，包括线粒体疾病、能量处理障碍、神经退行性疾病和衰老疾病，或者用于治疗或抑制具有一种或多种炎症和/或氧化应激生物标志物的肝脏或肾脏疾病，或者用于调节一种或多种能量生物标志物，使一种或多种能量生物标志物正常化，或增强一种或多种能量生物标志物，其中这些化合物是芳基和杂芳基间苯二酮衍生物。

  公开号：

  WO2018129411A1

文献信息

• SODIUM ION CHANNEL INHIBITORS AND PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF AND USES THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD.

  公开号：US20200048209A1

  公开（公告）日：2020-02-13

  The present disclosure discloses sodium ion channel inhibitors, pharmaceutically acceptable salts and polymorphs thereof, and uses thereof. Specifically, the present disclosure discloses a polymorph of a compound of formula (X) and a preparation method thereof. The preparation method of the present disclosure is simple in operation and suitable for industrialization. The polymorph prepared by the preparation method has advantages of good stability, low hygroscopicity and high water solubility.

  本公开揭示了钠离子通道抑制剂，其药用盐及其多型体，以及其用途。具体地，本公开揭示了一种化合物(X)的多型体及其制备方法。本公开的制备方法操作简单，适合工业化生产。由该制备方法制备的多型体具有良好的稳定性、低吸湿性和高水溶性的优点。
• AZAINDAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zhang Penglie

  公开号：US20110098308A1

  公开（公告）日：2011-04-28

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一些化合物，它们作为CCR1受体的有效拮抗剂，并具有体内抗炎活性。这些化合物通常是芳基哌嗪衍生物，可用于制备药物组合物，治疗CCR1介导的疾病的方法，以及作为竞争性CCR1拮抗剂鉴定的控制物。
• 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES
  申请人：Li Lianfa

  公开号：US20120010214A1

  公开（公告）日：2012-01-12

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一些化合物，它们作为CCR1受体的有效拮抗剂，并具有体内抗炎活性。这些化合物是3-咪唑基吡唑并[3,4-b]吡啶衍生物，可用于制备药物组合物、治疗CCR1介导的疾病的方法，并作为竞争性CCR1拮抗剂鉴定的控制物。
• 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES
  申请人：ChemoCentryx Inc.

  公开号：US20130184289A1

  公开（公告）日：2013-07-18

  Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

  提供了一些化合物，它们作为CCR1受体的强效拮抗剂，并具有体内抗炎活性。这些化合物是3-咪唑基吡唑并[3,4-b]吡啶衍生物，可用于制备药物组合物，治疗CCR1介导的疾病的方法，以及作为竞争性CCR1拮抗剂鉴定的控制物。
• [EN] GPR84 ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES DE GPR84 ET LEURS UTILISATIONS
  申请人：LIMINAL BIOSCIENCES LTD

  公开号：WO2022167457A1

  公开（公告）日：2022-08-11

  The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.

  本发明提供了式（I）化合物，其组成物以及使用它们来抑制GPR84和治疗GPR84介导的疾病的方法。